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Cardioprotection by Controlling Hyperamylinemia in a “Humanized”
Diabetic Rat Model
Sanda Despa, PhD; Savita Sharma, PhD; Todd R. Harris, PhD; Hua Dong, PhD; Ning Li, PhD; Nipavan Chiamvimonvat, MD;
Heinrich Taegtmeyer, MD, DPhil; Kenneth B. Margulies, MD; Bruce D. Hammock, PhD; Florin Despa, PhD
Background-—Chronic hypersecretion of the pancreatic hormone amylin is common in humans with obesity or prediabetic insulin
resistance and induces amylin aggregation and proteotoxicity in the pancreas. We recently showed that hyperamylinemia also
affects the cardiovascular system. Here, we investigated whether amylin aggregates interact directly with cardiac myocytes and
whether controlling hyperamylinemia protects the heart.
Methods and Results-—By Western blot, we found abundant amylin aggregates in lysates of cardiac myocytes from obese patients,
but not in controls. Aggregated amylin was elevated in failing hearts, suggesting a role in myocyte injury. Using rats overexpressing
human amylin in the pancreas (HIP rats) and control myocytes incubated with human amylin, we show that amylin aggregation at
the sarcolemma induces oxidative stress and Ca2+ dysregulation. In time, HIP rats developed cardiac hypertrophy and left-
ventricular dilation. We then tested whether metabolites with antiaggregation properties, such as eicosanoid acids, limit myocardial
amylin deposition. Rats were treated with an inhibitor of soluble epoxide hydrolase, the enzyme that degrades endogenous
eicosanoids. Treatment doubled the blood concentration of eicosanoids, which drastically reduced incorporation of aggregated
amylin in cardiac myocytes and blood cells, without affecting pancreatic amylin secretion. Animals in the treated group showed
reduced cardiac hypertrophy and left-ventricular dilation. The cardioprotective mechanisms included the mitigation of amylin-
induced cardiac oxidative stress and Ca2+ dysregulation.
Conclusions-—The results suggest blood amylin as a novel therapeutic target in diabetic heart disease and elevating blood levels
of antiaggregation metabolites as a pharmacological strategy to reduce amylin aggregation and amylin-mediated cardiotoxicity.
( J Am Heart Assoc.2014;3:e001015 doi: 10.1161/JAHA.114.001015)
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T he mechanisms by which obesity and prediabetic insulinresistance predispose to cardiac dysfunction are com-
plex and not completely understood.1–9 We have recently8
identified toxic amylin deposits in heart samples from
individuals with heart failure (HF) and obesity or type-2
diabetes (T2D), but not in controls. However, determining the
underlying cardiotoxic mechanism remains a key knowledge
gap, especially since such deposits may represent a previ-
ously unknown potential therapeutic target. Here, we focus on
(1) characterizing a possible link between cardiac amylin
pathology and HF in humans with obesity; and (2) testing
clinically relevant therapeutic strategies in an animal model of
the pathological process.
Amylin, also known as islet amyloid polypeptide, is an
amyloidogenic hormone cosecreted with insulin by pancre-
atic b-cells.10 Amylin plays a paracrine role in restraining
insulin secretion and is also known to bind to brain neuron
receptors, inducing an anorexic effect.10 People with obesity
or prediabetic insulin resistance show increased secretion of
amylin.10–13 With increased secretion (hyperamylinemia),
human amylin forms small aggregates (or oligomers) in the
secretory vesicles of b-cells14 and amyloid fibrils extracel-
lularly, in the islet.10,14–18 The oligomerized amylin is
cytotoxic, disrupts cellular membranes, and may also act
as nonselective ion channels.14–18 Clumping together amylin
oligomers of various sizes may form amyloid fibrils and
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plaques, which are believed to be relatively inert.14–18
Oligomerization of amylin induces oxidative19,20 and inflam-
matory21 stress in the pancreas, thus contributing to b-cell
apoptosis and development of T2D. The vast majority of
patients with T2D show amylin deposition in pancreatic
islets,10 demonstrating the exposure to hyperamylinemia.
Recent studies8,9,22 indicate that hyperamylinemia may also
contribute to the complications of diabetes by promoting
toxic accumulation of amylin aggregates outside the pan-
creas, in kidneys,9 heart,8 and brain.22 In the heart, amylin
deposition is specific to obesity or T2D.8 Neither nonfailing
nor failing hearts from lean, nondiabetic patients showed
amylin accumulation.8 Using a rat model of T2D expressing
human amylin in the pancreas (the HIP rat), we found that
cardiac accumulation of oligomerized amylin begins in
prediabetes and is associated with diastolic dysfunction
and cardiac hypertrophy.8 We have also shown that the
transition to full-blown T2D exacerbates amylin-induced
cardiac effects in HIP rats.23 In contrast, age- and blood
glucose–matched rats expressing only wild-type (nonamy-
loidogenic) rat amylin, which develop T2D associated with
other pathological defects in the pancreatic b-cells,24 display
cardiac dysfunction after the onset of T2D.8,24 These
studies8,24 suggest that myocardial accumulation of oligo-
merized amylin may accelerate diabetic heart dysfunction in
humans.
Epoxyeicosatrienoic acids (EETs) are signaling molecules
produced from arachidonic acid by cytochrome P450
epoxygenases25 and have several isomers with various
functions.24–29 EETs are primarily degraded by soluble
epoxide hydrolase (sEH), which transforms them to less
lipophilic and more readily conjugated 1,2-diols (dihydroxye-
icosatrienoic acids).28 Pharmacological inhibition or genetic
deletion of sEH elevates EETs, which was shown to have
various therapeutic effects in animal models of metabolic
disorders and cardiovascular disease.24,28–31 For example,
we showed recently24 that pharmacologically increased
levels of EETs improve glucose homeostasis in diabetic
rats.24 Because some EET isomers have antiaggregation
effects and reduce proteinaceous deposition on blood
vessels,26,27 we hypothesized that increasing the blood
levels of EETs may also limit the infiltration of toxic amylin
aggregates in the heart.
The aims of the present study were twofold. First, we
tested whether amylin aggregates attach to/incorporate into
human cardiac myocytes and how incorporated amylin levels
correlate with heart function (i.e., failing/nonfailing) and
diabetes status in humans. Secondly, we used the HIP rat
model to test the hypothesis that EETs limit cardiovascular
accumulation of aggregated amylin, thus preserving myocar-
dial structure and function. We anticipate that the results are
of relevance to heart failure in diabetes.
Methods
Human Samples
Failing human hearts were obtained at the time of orthotopic
heart transplantation at the Hospital of University of Penn-
sylvania. Nonfailing hearts from obese and lean individuals
were from organ donation. Tissue specimens were obtained in
accordance with Institutional Review Board approval, and
informed consent was obtained prospectively in all cases. The
study includes both transmural left ventricular myocardial
samples and isolates of enriched cardiac myocytes obtained
from 20 hearts divided into 4 pathologically distinct groups.
O-HF forms the group of obese patients (body mass index
≥30) who developed overt T2D within 1 year post-transplan-
tation (N=5), when all patients are treated with systemic
corticosteroids as part of the standard immunosuppressive
regimen. Hence, we speculated that these patients were in
the prediabetic state at the time of heart transplant. This
group included individuals with both ischemic and nonis-
chemic cardiomyopathy. We also assessed the level of
oligomerized amylin in myocyte lysates from nonfailing hearts
of obese humans (O-NF; N=6). Nonfailing hearts from healthy,
nonobese (body mass index <30) individuals (L-NF; N=4) and
failing hearts from lean patients (L-HF; N=5) without T2D
served as negative controls. All patients in the L-HF group had
nonischemic dilated cardiomyopathy. All cardiac myocyte
isolates used in the present study were also used in the
cohorts reported in our previous publication.8
Experimental Animals and Treatment
In contrast to human amylin, rodent amylin does not form
amyloid and is not cytotoxic.10 Therefore, to address mech-
anistically the impact of a “human” hyperamylinemia on
myocardial structure and function, we used a diabetic rat
model transgenic for human amylin (the HIP rat; Charles River
Laboratory). HIP rats express human amylin in the pancreatic
b-cells on the insulin II promoter. By 5 months of age, they
show impaired fasting glucose and have a 3-fold increase of
amylin secretion,32 similar to humans with hyperamylinemia.
This causes amylin aggregation and deposition in pancreas32
and peripheral organs, including the heart, as we showed
recently.8 Pancreatic deposition of amylin leads to gradual
decline of b-cell mass and T2D by 10 to 12 months of age.32
Age-matched wild-type (WT) littermates were used as nondi-
abetic controls. The investigation conforms to the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23,
revised 1996) and was approved by the Institutional Animal
Care and Use Committees at University of Kentucky and
University of California, Davis. A total of n=17 prediabetic
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male HIP rats (7 months of age) and n=15 age-matched WT
rats were used in this study.
To increase plasma eicosanoids levels, the animals were
treated with APAU (1-(1-acetypiperidin-4-yl)-3-adamantanylu-
rea, UC1153, AR9281), a sEH inhibitor synthesized by the
method of Jones et al33 Animals in the APAU treatment group
(HIP-T group; N=11) received APAU in their drinking water for
13 weeks, starting from the onset of the prediabetic state (ie,
when the blood glucose level was in the 15030 mg/dL, or
8.31.5 mmol/L, range for 2 consecutive readings). APAU
was formulated in polypropylene glycol at a concentration of
10 mg/mL with 30 minutes sonication and then added to
drinking water at a final concentration of 1%. The animals had
unrestricted access to water. Prediabetic HIP rats in the
untreated group (HIP-UT; n=6) received the same amount of
polyethylene glycol, a neutral biocompatible polymer. We
calculated the minimum sample size with a 2-tail t test
considering (1) the standardized mean difference in cardiac
amylin level derived from Figure 4B in reference [8] (1.5);
(2) a=0.05; and (3) 1b=0.8. The calculation was performed
using GPower 3.1.9.2 software (University of Dusseldorf) and
yielded 9 animals per treatment group. Thus, our study was
adequately powered.
Nonfasting blood glucose levels were measured biweekly
(morning time) with a glucometer (One Touch Blood Glucose
Meter; LifeScan, Inc). Plasma levels of insulin and amylin
(total) in fasted rats were measured by enzyme-linked
immunosorbent assay. At the end of the 13-week treatment
period, blood levels of APAU and EET were measured
by liquid chromatography/tandem mass spectrometry as
before.24
In Vivo Echocardiography
In vivo echocardiography was performed at the beginning and
at the end of the 13-week treatment period using M-mode
imaging as previously described.8
Immunochemistry
Western blot analysis and immunohistochemistry were used
to test amylin accumulation in cardiac specimens. Western
blot analysis was performed on tissue (heart and pancreas)
homogenates and lysates from cardiac myocytes and blood
cells. Tissue was homogenized in buffer containing 10 mmol/
L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 0.1% sodium dodecyl
sulfate, 1% Triton X-100, 1% sodium deoxycholate, 5 mmol/L
EDTA, 1 mmol/L NaF, 1 mmol/L sodium orthovanadate, and
protease and phosphatase inhibitor cocktail (Calbiochem, San
Diego, CA). Isolated cardiac myocytes were lysed in lysis
buffer containing 1% NP-40, 150 mmol/L NaCl, 10 mmol/L
Tris-HCl, 2 mmol/L EGTA, 50 mmol/L NaF, and protease and
phosphatase inhibitor cocktail (Calbiochem). Blood samples
were centrifuged at 2000 g to separate the plasma from the
blood cells, which were then lysed with the buffer described
above. For heart samples, equal loading was verified by
reprobing with anti-GAPDH (6C5) antibody (monoclonal,
ab8245; Abcam Inc, Cambridge, MA). The primary antibody
was a polyclonal antiamylin antibody (T-4157; Bachem-
Peninsula Laboratories, San Carlos, CA) that recognizes both
human and rat amylin (the latter with higher avidity8). The
results were verified using a second antihuman amylin
antibody (polyclonal, raised in rabbit, LS-C20521; Lifespan
Biosciences, Seattle, WA). To verify specific staining of
protein bands, samples were loaded onto a gel in duplicate
and, after blotting and blocking, the membrane was cut and
one half was incubated with the antiamylin antibody while the
other half was incubated without the primary. Both halves
were then incubated with the secondary antibody (biotinylat-
ed goat antirabbit IgG antibody BA-1000; Vector Laboratories,
Burlingame, CA) and developed and imaged together. No
staining was apparent in the absence of the primary antibody
(not shown; for a detailed analysis, see reference [8]). The
specificity of the antiamylin staining in immunohistochemistry
studies was demonstrated by incubating human pancreas
sections only with the secondary antibody (not shown; for a
detailed analysis, see reference [8]).
Signal intensity analysis was performed in Image J. For
each gel, we averaged the signal intensity of the correspond-
ing bands for the control samples. Then, we normalized the
signal intensity in all lanes to this average. This procedure was
repeated on at least 4 gels. For each sample, the normalized
signal intensity was averaged.
Quantitative Real-Time Polymerase Chain
Reaction
Quantitative real-time polymerase chain reaction was used to
assess the expression level of human and rat amylin in the
pancreas and heart as previously described.22
Adult Cardiac Myocyte Isolation and
Measurement of Cell Size
Rats were anesthetized by intraperitoneal injection of pento-
barbital (1 mg/g). When deep anesthesia was reached,
hearts were excised quickly, placed on a Langendorff
perfusion apparatus, and perfused with buffer containing
1 mg/mL collagenase. When the heart became flaccid, the
left ventricular tissue was cut into small pieces, dispersed,
and filtered. Human cardiac myocytes were also isolated by
collagenase perfusion, as described previously.34 The stan-
dard Tyrode’s solution used in experiments with live myocytes
contained (in mmol/L): 140 NaCl, 4 KCl, 1 MgCl2, 10 glucose,
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5 HEPES, and 1 CaCl2 (pH=7.4). All experiments were done at
room temperature (23 to 25°C). To measure myocyte size,
the midsection was imaged with a confocal microscope and
we measured the cell length and width using Image J.
Myocyte area was calculated both as length9width and by
tracing the external membrane of the cell and measuring the
area inside with ImageJ, which produced essentially similar
results.
Incubation of Isolated Myocytes With
Recombinant Human Amylin
The amylin oligomerization reaction was started in saline
solution at 37°C using 50 lmol/L recombinant human
amylin, which is the concentration at which this peptide
forms oligomers under physiological conditions in the pan-
creas.15,16 Myocytes were then incubated with the preformed
amylin oligomers for 2 hours at room temperature.
Electron Microscopy Imaging
Transmission electron microscopy imaging was done as
previously described.24 Briefly, myocytes were frozen rapidly
and embedded in Eponate-12 resin. Blocks were cut into 70-
nm-thick sections. Serial sections were collected on slot grids
covered with a 50-nm Formvar support film and visualized on
the transmission electron microscope (JEM-1230; JEOL)
operated at 120 keV. Images of each section (5 images per
block) were recorded at 2 lm defocus on a 204892048-
pixel charge-coupled device camera (TVIPS, Gauting, Ger-
many) and at nominal magnification of either 91000 or
92500, yielding an effective pixel size of 11 or 4.4 nm,
respectively.
Intracellular Ca2+ Measurements
Intracellular Ca2+ measurements were performed with Fluo-4.
Data are expressed as F/F0, where F0 is the fluorescence
signal in resting myocytes, to make the signal independent of
the amount of dye loaded into myocytes.
ROS Production Measurements
Myocytes were loaded with the fluorescent indicator 5-(and-
6)-chloromethyl-20,70-dichlorodihydrofluorescein diacetate
acetyl ester (CM-H2DCFA; Invitrogen), 10 lmol/L for 15
minutes, and imaged with a confocal microscope (excita-
tion=488 nm, emission >505 nm). Myocytes were electrically
stimulated at 1 Hz in the presence of isoproterenol (1 lmol/
L), and reactive oxygen species (ROS) production was
calculated as the slope of the increase in CM-H2DCFA
fluorescence.
Statistical Analysis
Data are expressed as meanSEM. For data that passed the
D’Agostino and Pearson normality test, statistical discrimi-
nations were performed using (1) 2-tailed unpaired Student t
test when comparing 2 groups; (2) 1-way analysis of
variance with the Bonferroni’s post-hoc test when comparing
multiple groups; and (3) 2-way analysis of variance when
comparing multiple groups for multiple conditions. When the
sample size was too small to perform the normality test,
data were analyzed with nonparametric tests (Mann–Whitney
when comparing 2 columns, Kruskal–Wallis followed by
Dunn’s post-test when comparing multiple columns). In
Figures 3E, 7, 8, and 9B, data from multiple myocytes from
the same animal were averaged and the resulting values per
animal were averaged for each group. Statistical analysis
was done in GraphPad Prism version 5.0 for Windows
(GraphPad Software, La Jolla, CA). P<0.05 was considered
significant.
Results
Oligomerized Amylin Incorporates Within
Myocytes in Prediabetic Humans and HIP Rats
To test whether aggregated amylin incorporates directly
within cardiac myocytes and how the level of incorporated
amylin correlates with heart function (failing/nonfailing) and
diabetes status in humans, we analyzed left ventricular
myocyte lysates from 4 pathologically distinct groups of
patients. The O-HF group included obese patients (body
mass index ≥30) with heart failure who developed overt T2D
during the first year post-transplantation. Patients in this
group were likely in the prediabetic state at the time of heart
transplant. The O-NF group consisted of obese individuals
without heart failure. Nonfailing hearts from lean individuals
(L-NF) and failing hearts from nonobese (body mass index
<30) nondiabetic patients (L-HF) served as negative controls.
Western blot analysis showed that the level of oligomerized
amylin (ie, trimers, tetramers, and octamers) was signifi-
cantly higher in myocyte lysates from the O-HF group
compared to those from L-NF and L-HF control groups
(Figure 1A and 1B). Aggregated amylin was even elevated in
the O-NF group (Figure 1A and 1B), indicating an early
process of amylin aggregation. The Western blot experiments
were performed under several conditions (with and without
dithiothreitol and sodium dodecyl sulfate) to examine soluble
and insoluble fractions of aggregated amylin in myocytes
(Figure 1C). The results show that nonreducing and nonde-
naturing conditions preserve large amylin aggregates
(>150 kDa) that may “intrinsically” form in cells and tissues.
Adding dithiothreitol and sodium dodecyl sulfate in the
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sample buffer and gel breaks amylin aggregates, resulting in
lower-molecular-weight bands as in Figure 1A and 1B. The
lower-molecular-weight amylin aggregates observed in Fig-
ure 1A and 1B remain insoluble to dithiothreitol and sodium
dodecyl sulfate and are likely formed by intermolecular
interactions.
Figure 1D and 1E shows that amylin trimers and tetramers
are present in both left ventricular protein homogenates and
myocyte lysates from the same patient. This result suggests
that amylin aggregates are also prominent in nonmyocytes
and/or the extracellular matrix. In fact, the level of aggre-
gated amylin is higher in protein homogenates, suggesting
that aggregated amylin is even more prevalent outside of the
myocytes. Indeed, immunohistochemistry data show amylin-
positive plaques in heart parenchyma from diabetic patients
(Figure 2A; blue arrows) but not in healthy hearts from
nondiabetic individuals (Figure 2C). Serial staining with amylin
and Congo Red suggested that amylin may form amyloid-like
structures in the diabetic human heart (Figure 2B). The
presence of amylin outside of cardiac myocytes may not be
static and could promote cardiac myocyte uptake. For
example, amylin is known to bind to the calcitonin gene-
related peptide receptor,10 which could mediate the amylin
uptake in cardiac myocytes.
Amylin also accumulates in coronary arteries and cardiac
parenchyma in the HIP rat (Figure 2D). Transcript analysis by
quantitative real-time polymerase chain reaction showed no
presence of human amylin mRNA in HIP rat hearts (Figure 2E;
note logarithmic scale and scale break). Thus, the amylin
incorporated in HIP rat hearts comes from the circulation,
originating in the pancreas, as in humans. Hence, the HIP rat
is a clinically relevant animal model to examine potential
therapeutic strategies to limit cardiovascular accumulation of
aggregated amylin.
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Figure 1. Oligomerized amylin incorporates within cardiac myocytes in prediabetic humans. A and B,
Western blot analysis with an antiamylin antibody on left ventricular myocyte lysates from human hearts
demonstrates the presence of amylin trimers (12 kDa), tetramers (16 kDa), and octamers (32 kDa)
attached to the sarcolemma or inside the myocytes (representative of 4 experiments). Nonfailing hearts (L-
NF) and failing hearts (L-HF) from nonobese patients served as negative controls. C, Western blot
experiments with antiamylin antibody on HIP myocyte lysates performed with and without DTT and SDS in
the sample and running buffers. D and E, Western blot analysis with an antiamylin antibody showing the
presence of amylin aggregates (trimers and tetramers) in both left ventricle protein homogenates (h) and
myocyte lysates (m) from the same patient from O-HF (C) and O-NF (D) groups. *P<0.05 vs L-NF. #P<0.05
vs O-NF. DTT indicates dithiothreitol; HIP, human amylin in the pancreas; O-HF, obese patients with heart
failure; O-NF, obese patients with nonfailing hearts; SDS, sodium dodecyl sulfate.
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Figure 2. Amylin incorporates in blood vessels and parenchyma in failing hearts from diabetic
humans and HIP rat hearts. A, Immunohistochemistry analysis of failing hearts from T2D
patients with an antiamylin antibody shows amylin deposits (brown) incorporated in the blood
vessel wall, perivascular space, and on the sarcolemma of neighboring cardiac myocytes (blue
arrows). The inset shows amylin deposition in the basement membranes and co-localization with
neutrophils. B, Amylin (brown) is present in atherosclerotic lesions. Staining of the next section
with Congo red (lower panel) indicates that amylin deposition may form amyloid-like structures
(pink) within myocardial interstices. C, Cardiac parenchyma from nonfailing human hearts shows
no amylin deposits. D, Immunohistochemistry with an antiamylin antibody shows that amylin
(brown; red arrows) incorporates into blood vessel walls and heart parenchyma in HIP rat. E,
Quantitative real-time PCR shows no presence of human amylin mRNA in the HIP rat heart. Note
the logarithmic scale and scale break. N=8 HIP rat heart samples and N=4 human pancreas and
rat samples were analyzed in this study. WT rat heart samples (N=8) served as negative controls.
HIP indicates human amylin in the pancreas; PCR, polymerase chain reaction; T2D, type 2
diabetes; WT, wild-type.
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Amylin Deposition Causes Oxidative Stress in
Cardiac Myocytes
The interaction of aggregated amylin with sarcolemma may
affect myocyte function through various mechanisms. We have
previously shown that aggregated amylin incorporates in the
sarcolemma, inducing sarcolemmal Ca2+ leak and activation of
Ca2+-mediated hypertrophy signaling pathways.8 Amylin
aggregation is also known as a potent generator of oxidative
stress in both cell culture and animal models.10,19,20 Therefore,
we measured the production of ROS in WT rat cardiac
myocytes incubated with preformed amylin aggregates for
2 hours. The level and characteristic molecular weights of
amylin aggregates found in lysates from myocytes incubated
under these conditions are comparable to those found in HIP
rat myocyte lysates (Figure 3A). Thus, short-term incubation
of myocytes with exogenous human amylin aggregates
mimics the in vivo attachment of amylin aggregates to
myocytes in HIP rat hearts. Moreover, the interaction of
oligomerized human amylin with cardiac myocytes alters
cardiac myocyte structure. Electron microscopy images of
isolated WT cardiac myocytes incubated with exogenous
human amylin aggregates show significant alterations of
cardiac myocyte structure, including sarcolemmal damage
(Figure 3B, arrows) and mitochondrial disarrangement
(Figure 3B, square). In contrast, control WT cardiac myocytes
present intact sarcolemmal and internal structures (Fig-
ure 3C).
Myocyte ROS production was assessed with CM-H2DCFA.
Dye-loaded cells were electrically stimulated in the presence
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Figure 3. The interaction of oligomeric amylin with sarcolemma causes oxidative stress in cardiac
myocytes. A, Western blot with an antiamylin antibody on lysates from control myocytes incubated with
preformed amylin aggregates (WT+Amy), HIP rats myocytes (HIP), and control WT cells (WT). Oligomers
were preformed by incubating 50 lmol/L exogenous human amylin for 2 hours at room temperature.
B and C, Representative transmission EM images of WT rat cardiac myocytes incubated with 50 lmol/L
oligomerized human amylin for 2 hours (B) and control myocytes (C). Arrows point to alterations in
sarcolemmal structure. The square guides the eye to the mitochondrial disarrangement. D, Representative
example of ROS production measurement with the fluorescent indicator CM-H2DCFA. Myocytes loaded with
CM-H2DCFA were electrically stimulated at 1 Hz in the presence of isoproterenol (ISO, 1 lmol/L), which
increased CM-H2DCFA fluorescence (from point a to point b), indicating ROS (H2O2) production. At the end,
pacing was stopped and H2O2 (1 mmol/L) was washed in to verify the specificity of the signal (increased
fluorescence from b to c). ROS production was measured as the slope of fluorescence increase between the
points a and b. E, ROS production was compared in control myocytes (Ctl; 11 myocytes from 3 rats) and
myocytes incubated with preformed amylin oligomers (amylin; 8 myocytes, 3 rats), 400 mg/dL glucose
(gluc; 7 myocytes, 3 rats), and a combination of glucose (400 mg/dL) and preformed amylin oligomers
(amylin+gluc; 7 myocytes, 3 rats). *P<0.05, **P<0.01. CM-H2DCFA indicates 5-(and-6)-chloromethyl-
20,70-dichlorodihydrofluorescein diacetate acetyl ester; EM, electron microscopy; HIP, human amylin in the
pancreas; ROS, reactive oxygen species; WT, wild-type.
DOI: 10.1161/JAHA.114.001015 Journal of the American Heart Association 7
Cardioprotection by Controlling Hyperamylinemia Despa et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at UNIV OF KENTUCKY on February 16, 2016http://jaha.ahajournals.org/Downloaded from 
of isoproterenol (ISO) and the slope of the fluorescence
increase was taken as a measure of ROS production
(Figure 3D). At the end, pacing was stopped and H2O2
(1 mmol/L) was washed in to verify the specificity of the
signal. Incubation with amylin greatly increased myocyte ROS
production (by 8721%; Figure 3E). By comparison, incuba-
tion of cardiac myocytes with 400 mg/dL (22.2 mmol/L)
glucose, for the same duration, increased ROS production by
only 4012% (Figure 3E). Thus, in addition to altering Ca2+
cycling,8 the interaction of amylin aggregation with the
sarcolemma induces sarcolemmal damage and oxidative
stress.
Eicosanoids Limit Cardiovascular Accumulation
of Aggregated Amylin
Because EETs reduce proteinaceous deposition on blood
vessels and have antiaggregation properties,26,27 we hypoth-
esized that increasing the EETs level in the blood may limit the
infiltration of aggregated amylin in the heart. To elevate blood
levels of EETs, HIP rats were treated with the sEH inhibitor
APAU33 for 13 weeks (HIP-T group). The study was started
when rats were in the prediabetic state (nonfasting blood
glucose in the 150 to 200 mg/dL range [http://
www.nlm.nih.gov/medlineplus/ency/article/000313.htm]).
Age-matched HIP rats in the untreated group received the
same amount of polyethylene glycol, a neutral biocompatible
polymer (HIP-UT group). sEH inhibition increased plasma
levels of EETs in treated HIP rats (Figure 4A and Table 1), with
the EETs/dihydroxyeicosatrienoic acids ratio being almost
double in treated compared to untreated HIP rats at the end
point of the study (Figure 4A). Thus, APAU efficiently
increases EETs level, consistent with our previous results in
a different diabetic model.24 Western blot analysis of
ventricular myocyte lysates from treated and untreated HIP
rats shows that the treatment significantly reduced the
incorporation of aggregated amylin into cardiac myocytes
(Figure 4B and 4C). Thus, elevating the blood level of pro-
fibrinolytic EETs lowers cardiac accumulation of aggregated
amylin.
Reduced cardiac accumulation of aggregated amylin in
HIP-T rats is not due to a lower level of amylin secreted in
the blood. Plasma amylin (Figure 5A), along with insulin
(Figure 5B) and glucose (Figure 5C), were compared in
animals from WT, HIP-T, and HIP-UT groups at various time
points. Animals in HIP-T and HIP-UT groups had similar
plasma levels of amylin (and insulin), suggesting that amylin
secretion from pancreatic b-cells is not altered by inhibiting
sEH. Intriguingly, the levels of aggregated amylin in the
blood pellet (ie, amylin aggregates attached to blood cells)
are significantly lower in animals from the HIP-T group
(Figure 6A). Thus, EETs may either dissociate the amylin
aggregates and/or inhibit their attachment to membranes.
To test this hypothesis, we incubated WT cardiac myocytes
with preformed amylin aggregates in the presence or
absence of 5 lmol/L 14,15-EET. Figure 6B shows that
co-incubation with 14,15-EET considerably reduced the
deposition of amylin in the sarcolemma. Adding 14,15-EET
after incubating the myocytes with amylin aggregates for
2 hours disentangled some small amylin aggregates from
the sarcolemma (the Amy/EET column in Figure 6C).
Intriguingly, preconditioning the myocytes by exposure to
14,15-EET prior to incubation with aggregated amylin
potentiated the amylin attachment to the sarcolemma (the
EET/Amy column in Figure 6C). To test whether EETs are
also able to dissociate amylin aggregates, we investigated
the effect of 14,15-EET in solution (Figure 6D). Co-incuba-
tion of aggregated amylin with 5 lmol/L 14,15-EET
reduced the levels of amylin dimers and trimers in solution.
Similar effects were produced by plasmin (Figure 6D),
another protein known for its profibrinolytic properties.
These results suggest that EETs limit cardiovascular
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Figure 4. EETs limit accumulation of oligomeric amylin at cardiac
myocyte sarcolemma. A, The ratio of total EETs to DHETs in plasma
from APAU-treated and untreated HIP rats at the end of the
13 weeks study period. B, Top panel shows representative (of 4
experiments) Western blot with an antiamylin antibody on ventric-
ular myocyte lysates from treated (HIP-T) vs (HIP-UT) untreated HIP
rats. Bottom panel displays the intensity analysis of the molecular
weight bands corresponding to amylin trimers (12 kDa), tetra-
mers (16 kDa), 16-mers (64 kDa), and 20-mers (80 kDa) in
the top panel. C, Total oligomerized amylin in myocyte lysates from
rats in HIP-T and HIP-UT groups obtained by integrating all
molecular weight bands in (B). *P<0.05. APAU indicates (1-
(1-acetypiperidin-4-yl)-3-adamantanylurea; DHETs, dihydroxyeicos-
atrienoic acids; EETs, epoxyeicosatrienoic acids; HIP, human amylin
in the pancreas.
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accumulation of aggregated amylin by 2 likely mechanisms:
(1) binding to amylin aggregates, which blocks the attach-
ment to cell membranes; and (2) disentangling circulating
amylin aggregates, consistent with the antiaggregation
properties of EETs.26,27 Still, further investigation is needed
to elucidate the mechanisms by which EETs reduce amylin
accumulation.
Rodent amylin does not form amyloid.10 However, rodent
amylin may interact with human amylin in the transgenic rat
forming differently packed, mixed rodent amylin–human
amylin oligomers. A different packing of mixed amylin
oligomers may explain the variability in molecular weights of
amylin aggregates identified in HIP rats (Figure 4B) versus
amylin oligomers formed in an ex vivo formulation (Figure 3A)
versus oligomerized amylin identified in cardiac tissue from
humans (Figure 1A).
Limiting Myocardial Accumulation of Aggregated
Amylin Reduces the Oxidative Stress and
Preserves Myocyte Ca2+ Cycling
The mechanism underlying the beneficial effects of reducing
myocardial accumulation of toxic aggregated amylin is likely
multimodal. Because aggregated amylin is a source of cardiac
oxidative stress and Ca2+ dysregulation, we investigated the
treatment outcome on these 2 pathological processes.
ROS production was significantly increased in myocytes
from untreated HIP rats versus WT (by 7016%, Figure 7), in
agreement with data in Figure 3E showing oxidative stress in
myocytes acutely exposed to amylin oligomers. Lowering
cardiac accumulation of aggregated amylin by APAU treatment
greatly reduced ROS production in HIP rat myocytes (Figure 7).
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Figure 5. Plasma amylin (A), insulin (B), and glucose (C) levels in
WT, HIP-T, and HIP-UT animal groups at various time points during
the study period. The initial increase of plasma amylin and insulin is
due to the onset of prediabetic insulin resistance in HIP rats, which
triggers compensatory secretion of the 2 hormones (ie, hyperin-
sulinemia and hyperamylinemia). N=10 HIP rats for treated group,
N=7 untreated HIP rats, and N=10 nondiabetic WT rats.
***P<0.001 vs WT; ###P<0.001 vs HIP-treated. HIP indicates
human amylin in the pancreas; WT, wild-type.
Table 1. Plasma Levels of EETs and Inactive DHETs in
Untreated and APAU-Treated HIP Rats
Treated Untreated
Epoxyeicosatrienoic acids, nmol/L
14,15-EET 18.35.2 7.62.8
11,12-EET 18.26.8 8.33.6
8,9-EET 6.71.8 4.21.9
5,6-EET 31.69.5 13.76.7
Dihydroxyeicosatrienoic acids, nmol/L
14,15-DHET 1.80.1 2.31.0
11,12-DHET 2.20.3 3.11.6
8,9-DHET 1.10.2 1.90.4
5,6-DHET 3.20.5 3.40.6
APAU indicates (1-(1-acetypiperidin-4-yl)-3-adamantanylurea; DHETs,
dihydroxyeicosatrienoic acids; EETs, epoxyeicosatrienoic acids.
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Alterations in myocyte [Ca2+]i regulation play an important role
in the pathophysiology of diabetic heart disease.35–38 We have
previously shown that dysregulation of myocyte Ca2+ cycling is
one of the early, direct effects induced by accumulation of
aggregated amylin in the heart.8,35 We now compared Ca2+
transients and sarcoplasmic reticulum Ca2+ load in cardiac
myocytes from HIP-UT and HIP-T rat groups and age-matched
WT rats at the end of the 13-week treatment period. Ca2+
transients were significantly smaller in myocytes from HIP-UT
rats compared to WT rats for all stimulation frequencies (0.2,
0.5, 1, and 2 Hz; Figure 8A), indicating impaired myocyte
contractility in HIP-UT rats. Deficient myocyte contractility in
HIP-UT rats is also suggested by the lower sarcoplasmic
reticulum Ca2+ content, which was measured as the amplitude
of the Ca2+ transient induced by 10 mmol/L caffeine (Fig-
ure 8B). Limiting the incorporation of aggregated amylin in
cardiac myocytes restored both Ca2+ transient amplitude and
sarcoplasmic reticulum Ca2+ load (Figure 8A and 8B). sEH
inhibition had no significant effect in WT rats (WT-T group;
Figure 8A and 8B). The decline of Ca2+ transients induced by
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Figure 6. EETs reduce the level of amylin oligomers circulating in the blood. A, Representative (of 4
experiments) Western blot with an antiamylin antibody on whole blood cell lysates from HIP rats in the
treated (T) and untreated (UT) groups. Bottom panel shows the band intensity analysis for these
experiments. B, Representative (of 3 experiments) Western blot with an antiamylin antibody on ventricular
myocyte lysates from control rats. Before lysis, myocytes were incubated for 2 hours in the absence (Ctl) or
in the presence of 50 lmol/L recombinant human amylin (Amy). Myocytes in the Amy+EET column were
incubated with 50 lmol/L human amylin and 5 lmol/L 14,15-EET. Co-incubation with EETs reduced the
attachment of amylin oligomers to cardiac myocytes. Bottom panel shows the band intensity analysis.
C, The effect of 5 lmol/L 14,15-EET on amylin attachment to the sarcolemma when added before (EET/
Amy) or after (Amy/EET) incubation of myocytes with oligomerized amylin. D, Representative Western blot
showing that 14,15-EETs and plasmin (both 5 lmol/L) limit oligomerization of recombinant human amylin
in saline solution (50 lmol/L amylin; 2 to 3 hours incubation time). *P<0.05; **P<0.01; ***P<0.001. EETs
indicates epoxyeicosatrienoic acids; HIP, human amylin in the pancreas.
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electrical stimulation and caffeine is mediated mainly by the
sarcoplasmic reticulum Ca2+-ATPase and the sarcolemmal
Na+/Ca2+ exchanger, respectively. In both cases, Ca2+ tran-
sient decay was significantly slower in myocytes from HIP-UT
rats versus WT rats (Figure 8C and 8D), in agreement with our
prior data8 showing reduced sarcoplasmic reticulum Ca2+-
ATPase and Na+/Ca2+ exchanger expression in diabetic HIP
rats. Both effects were partially mitigated by reducing cardiac
accumulation of aggregated amylin (Figure 8C and 8D).
Thus, the cardioprotective mechanisms of reducing accu-
mulation of toxic amylin aggregates in the heart include the
mitigation of amylin-induced oxidative stress and myocyte
Ca2+ alterations.
sEH Inhibition Reduces Cardiac Hypertrophy and
Left-Ventricular Dilation
Using the HIP rat model, we have previously shown that
cardiac accumulation of aggregated amylin leads to cardiac
hypertrophy and left-ventricular dilation even in the predia-
betic state.8,35 At the end of the treatment period, heart-
weight-to-body-weight (HW/BW) ratio (Figure 9A) and
myocyte surface area (Figure 9B) were markedly increased
in HIP-UT rats compared to WT littermates, consistent with
the development of cardiac hypertrophy. The larger myocyte
area was mainly due to an increase in cell length (1255 lm
in HIP versus 1016 lm in WT rats), while cell width was not
significantly affected (26.31.8 lm in HIP versus
22.81.5 lm in WT rats), consistent with eccentric hyper-
trophy. In addition, M-mode echocardiography showed signif-
icantly increased left ventricular end-diastolic diameter in HIP-
UT rats compared to WT rats (Figure 9C). Full echocardiog-
raphy data are included in Table 2. Limiting cardiovascular
accumulation of aggregated amylin significantly reduced both
cardiac hypertrophy (Figure 9A and 9B) and left ventricular
remodeling (Figure 9C) in HIP-T rats. Thus, controlling hype-
ramylinemia by reducing cardiovascular accumulation of
aggregated amylin with EETs preserves myocardial structure
and function in HIP rats.
Discussion
Present results indicate that amylin aggregation affects
directly cardiac myocytes in humans and that this patholog-
ical process starts in prediabetes (Figure 1A and 1B).
Moreover, significantly higher levels of amylin incorporated
in cardiac myocytes from O-HF individuals suggest a link of
hyperamylinemia and amylin aggregation with the develop-
ment of heart disease in humans. These data are consistent
with the pathological role of amylin aggregation within
(1) pancreas,10,14,19–21 kidneys,9 and brain22 in humans; and
(2) pancreas32 and heart8 in HIP rats. Using the HIP rat model,
we now demonstrated that limiting cardiovascular accumula-
tion of aggregated amylin by increasing eicosanoid activity
protects the heart (Figures 7 through 9). This study provides
proof of the concept that reducing the level of aggregated
amylin in the cardiovascular system ameliorates amylin’s
deleterious effects on heart function.
Cytotoxicity of “human” hyperamylinemia is associated
with the high propensity of human amylin to form amyloids,10
which is common to all amyloid-assembling proteins.39
Previous data40 demonstrated that cardiac myocyte-restricted
expression and accumulation of the amyloidogenic peptide
polyglutamine induces heart failure in mice. Presenilin,
another amyloidogenic peptide found in the heart, is also
associated with cardiac pathologies in humans.41 Similarly,
adding exogenous human amylin in cell culture promotes fibril
growth at the cell membrane,18 altering cell viability and
function, an effect that is also suggested by present results
(Figure 3B). Not surprisingly, even small human amylin
aggregates (trimers, tetramers) can induce cytotoxicity, which
may be triggered by their great ability to quickly and massively
insert into cell membranes and leading to the formation of
nonselective pores.8 For example, we have previously8 shown
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Figure 7. APAU treatment reduces amylin oligo-
mer-induced oxidative stress. ROS production mea-
sured with CM-H2DCFA in myocytes from WT (8
myocytes from4 rats), untreatedHIP (HIP-UT; 13 cells,
4 rats), and treated HIP (HIP-T; 9 cells,
3 rats) rats. *P<0.05, **P<0.01. APAU indicates (1-
(1-acetypiperidin-4-yl)-3-adamantanylure;CM-H2DCFA,
5-(and-6)-chloromethyl-20,70-dichlorodihydrofluo-
rescein diacetate acetyl ester; ROS, reactive oxygen
species; WT, wild-type.
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that incubation of intact cardiac myocytes with human amylin
for 1 to 2 hours leads to infiltration of small amylin oligomers
in the sarcolemma, which considerably increased sarcolem-
mal Ca2+ leak and altering vital Ca2+-mediated signaling. In
contrast, rodent amylin is not amyloidogenic due to 6 proline
substitutions in the amylin amino acid sequence.42 Hyperse-
cretion of rodent amylin in mice does not induce amyloid
deposition, b-cell loss, or T2D.43 Using the HIP rat model, we
determined mechanistically the impact of a “human” hypera-
mylinemia on the heart and demonstrated that controlling the
“human” hyperamylinemia protects the heart. Hence, our
study may potentially reveal a novel and important therapeu-
tic strategy in reducing/preventing cardiac complications of
T2D in humans.
The present results indicate that pro-fibrinolytic EETs can
control hyperamylinemia by mitigating cardiovascular accu-
mulation of aggregated amylin. The level of aggregated amylin
incorporated within cardiac myocytes is considerably lower
in HIP-T rats compared to HIP-UT rats (Figure 4). Moreover,
aggregated amylin was also reduced in blood cell lysates from
HIP-T rats compared to HIP-UT rats (Figure 6). Because
animals in treated and untreated groups have similar plasma
levels of amylin (Figure 5A) and insulin (Figure 5B), we infer
that (1) treatment does not alter pancreatic b-cell secretory
function; and (2) EETs interact directly with circulating amylin
aggregates and increase their solubility. In support to this
proposed mechanism, we found that EETs block both the
aggregation of recombinant human amylin in saline solution
(Figure 6D) and the acute incorporation of preformed amylin
aggregates in myocytes (Figure 6B). These results are
consistent with the profibrinolytic and antiaggregation prop-
erties of EETs.26,27
The mechanism underlying the beneficial effects of EETs on
the cardiovascular system is likely multimodal. EETs mediate
endothelium-dependent vasodilation,31 which lowers the
afterload and may contribute to reduced hypertrophy in the
treated rats, and are anti-inflammatory.31 Elevated EETs also
attenuate hyperglycemia,24,29,30 which we observed here as
well (Figure 5C). Indeed, only 40% of HIP-T rats developed
overt hyperglycemia (ie, nonfasting blood glucose >200 mg/
dL) at the end of the 13 weeks of treatment. In contrast, all
rats in the HIP-UT group progressed rapidly to overt hyper-
glycemia. It is also possible that EETs reduced the vascular
deposition of amylin oligomers. Nevertheless, our data
indicate that reducing the incorporation of aggregated amylin
in cardiac myocytes is a key component of the multimodal
mechanism31 of cardioprotection mediated by EETs in T2D
(Figure 10), by limiting amylin-induced cardiac oxidative
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stress (Figure 7) and myocyte Ca2+ dysregulation (Figure 8).
At the whole-heart level, HIP rats show abnormalities in left
ventricular structure (Figure 9). Such abnormalities typically
precede the onset of heart failure in individuals with cardiac
infiltrative diseases44 and are also important pathological
changes leading to the development of diabetic heart
disease.2–8 Elevated EETs blood levels preserve myocardial
structure and function in HIP rats. Our results are particularly
interesting in the context of recent data45 showing cardio-
protection in T2D by dietary supplementation with docosa-
hexaenoic acid (DHA), a naturally derived omega-3 fatty acid
and counterpart of EETs. EETs and DHA may have similar
mechanisms of cardioprotection that involve reducing path-
ological cardiac hypertrophy.
In summary, our study provides evidence in support of the
hypothesis that hyperamylinemia is directly implicated in
diabetic heart injury in humans and presents proof of concept
data for reducing the level of aggregated amylin in the
cardiovascular system and its deleterious effects on cardiac
function in an animal model. Our study also points to
circulating aggregated amylin as a novel therapeutic target in
diabetic cardiovascular disease and elevating EETs as an
innovative therapeutic strategy to limit circulation of amylin
aggregates and thus, the risk of cardiovascular disease in
patients with obesity and insulin resistance.
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ventricular dilation in HIP rats. A, Heart-weight-to-body-weight
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representative examples of myocytes from WT, HIP-UT, and HIP-T
groups; Bottom—average surface area (length9width) for WT,
untreated HIP, and treated HIP rat myocytes. C, Left-ventricular
end-diastolic diameter in WT, untreated HIP, and treated HIP rats
at the end of the 13-week study period. *P<0.05, **P<0.01,
***P<0.001. HIP indicates human amylin in the pancreas; LVEDD,
left-ventricular end-diastolic diameter; WT, wild-type.
Hyperamylinemia Insulin Resistance
Circulating
Amylin Oligomers
EETs
Attachment to 
Gluco-lipo-toxicity
Inflammation
Endothelial Dysfunction
Cardiac Myocytes
↑ROS Ca2+
Mishandling
Other Factors
Diastolic Dysfunction; Hypertrophy; 
Cardiac Dilation
Figure 10. Proposed mechanism: hyperamylinemia, a condition
secondary to insulin resistance, promotes amylin oligomer
attachment/incorporation to cardiac myocytes, leading to heart
dysfunction. The mechanism underlying the beneficial effects of
EETs on heart function is likely multimodal and includes an
efficient diminution of infiltration of oligomerized amylin in cardiac
myocytes. EETs indicates epoxyeicosatrienoic acids; ROS, reac-
tive oxygen species.
Table 2. Echocardiographic Parameters Before Starting the
Treatment (Baseline) and at the End of the 13-Week
Treatment Period in Treated (n=8) and Untreated (n=6) HIP
Rats
Baseline Treated Untreated
LVEDD, mm 8.00.4 8.20.2 9.00.2*
LVESD, mm 4.40.3 4.40.2 5.10.3
Fractional shortening, % 45.92.4 46.61.7 43.32.6
Ejection fraction, % 81.82.2 82.41.5 78.82.7
The mean echo parameters at baseline were similar between the treated and untreated
groups, so those data were pulled together. LVEDD indicates left-ventricular end-
diastolic diameter; LVESD, left-ventricular end-systolic diameter. Fractional shortening=
([LVEDDLVESD]/LVEDD)9100%.
*P<0.05.
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